GLP-1 medications are FDA-approved specifically for weight loss for more than half the adult population of the United States. Plan sponsors can take action to manage weight and other cardiodiabesity-related health challenges within their member population.

A report from the Evernorth Research Institute offers insights that can help health plans optimize cancer care.

To create a strong pipeline of early career technology talent, and create equitable opportunities for underrepresented students, Evernorth has partnered with Access Point – a program designed to provide accelerated hands-on technical training and mentorship.

We are taking a thoughtful and comprehensive approach to assessing biosimilar options that considers several factors.

COVID-19 and other recent events have likely exacerbated stress and depression among teenagers in the United States, who already struggle with mental health stigmas and access to medications and therapies.

Getting the most value out of your specialty drug management partner starts with asking the right questions.

The advancements that will accelerate the delivery of proper treatment, reduce administrative burden, and improve the overall care experience for patients and providers.